The development of custom antibodies is a critical component in advancing research and therapeutic innovation. Biointron, a Contract Research Organization (CRO) specializing in antibody expression services, provides comprehensive support to biotech companies seeking reliable, scalable, and high-quality solutions for their antibody production needs.
Expertise in Antibody Discovery and Expression
Biointron’s core strength lies in its expertise in the discovery, engineering, and expression of custom antibodies. The company employs advanced platforms for hybridoma development, phage display technology, and recombinant antibody expression to cater to a broad range of applications, including diagnostics, therapeutics, and basic research.
One of Biointron’s key offerings is Abinvivo, a Biointron brand that provides in vivo antibodies and reagents for research use. Biointron’s catalog products for in vivo research can be found at Abinvivo, where we have a wide range of Benchmark Positive Antibodies, Isotype Negative Antibodies, Anti-Mouse Antibodies, Bispecific Antibodies, and Antibody-Drug Conjugates.
Related: Abinvivo’s In Vivo Antibody Products: Differences in V3, V6, and V9
Abinvivo also integrates analytical validation as part of our services. This ensures that each batch of antibodies meets the purity, stability, and functional requirements critical for success in downstream applications.
Supporting Therapeutic Antibody Development
The therapeutic antibody market continues to grow, driven by innovations in immuno-oncology, autoimmune disease therapies, and infectious disease research. Biointron supports these efforts by offering services like humanization of monoclonal antibodies, a key step in transitioning murine-derived antibodies for human clinical applications.
A Trusted Partner for Antibody R&D
Biointron is committed to maintaining transparent communication and collaboration throughout the project lifecycle. Our team of scientists works closely with clients to ensure the antibody development process aligns with project goals, budgets, and timelines.
For biotech firms navigating complex research demands, partnering with Biointron offers a streamlined approach to custom antibody development. Our integrated solutions, technical expertise, and focus on quality provide the support necessary to bring innovative antibody-based products to market.
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
